Emerging Question On OTC Switches: Too Many Choices For Consumers?
This article was originally published in The Tan Sheet
When considering potential Rx-to-OTC switches, FDA advisory committees likely will weigh whether consumers will have too many choices in OTC categories to make safe selections. As more drugs switch, industry should consider retiring outdated and obsolete drugs, says FDA official Sandra Kweder said.
You may also be interested in...
Rx-to-OTC switch sponsors should not wait for FDA to act on NSURE before proposing innovative switch solutions, because reviewers are open to discussing ideas now, an agency official says. Some experts predict the new switch paradigm will not yield concrete regulatory changes, and are promoting other ways to expand OTC access.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.